

Claims


1. A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula III:



Formula III


wherein A is optionally substituted 3- to 6-membered cycloalkylene, optionally substituted 3- to 6-membered heterocycloalkylene, optionally substituted 6-membered arylene, optionally substituted 5- to 6-membered heteroarylene, optionally substituted C_2-C_4 alkylene, optionally substituted C_1-C_4 heteroalkylene or optionally substituted C_2-C_4 alkenylene;

Y^8 is  -NHC(O)-, -NHC(O)NH-, -NHC(O)NCH$_3$-, -NHC(O)O-, -NHC(S)-,

 -NHC(S)NH-, -NHS(O)$_2$-, or -NHS(O)$_2$NH-;

W is hydrogen, C_1-C_4 alkyl, optionally substituted C_1-C_3 heteroalkyl, optionally substituted 3- to 10-membered heterocycloalkyl, optionally substituted 3- to 10-membered cycloalkyl, optionally substituted 6- to 10-membered aryl, or optionally substituted 5- to 10-membered heteroaryl;

L has the structure of Formula VIIa or VIIb:





Formula VIIa or Formula VIIb

z is 0, 1, or 2;




X^9 is -NR^{L6}-, -C(O)-, or -S(O)$_2$-;

each of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} is, independently, hydrogen, halogen, hydroxyl, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, or optionally substituted C_1-C_6 heteroalkyl; or any two of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} together with the atoms to which they are attached and any intervening atoms to form an optionally substituted C_3-C_8 cycloalkyl or a 3- to 8-membered heterocyclyl; or R^{L1} and R^{L2} taken together form a bond;

wherein L does not have the structure of



; or

optionally, wherein L is not




;

X^4 and X^5 are each, independently, CH_2, $CH(CH_3)$ or NH;

R^{13} is optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted 3- to 6-membered cycloalkyl, optionally substituted 3- to 6-membered cycloalkenyl, optionally substituted 3- to 15-membered heterocycloalkyl, optionally substituted 6- to 10-membered aryl, or optionally substituted 5- to 10-membered heteroaryl;

R^2 is hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted 3- to 6-membered cycloalkyl, optionally substituted 3- to 7-membered heterocycloalkyl, optionally substituted 6-membered aryl, optionally substituted 5- or 6-membered heteroaryl;

R^{10} is hydrogen, hydroxy, optionally substituted C_1-C_6 alkoxy, optionally substituted C_1-C_3 alkyl, optionally substituted C_1-C_6 heteroalkyl, or optionally substituted 3- to 10-membered heterocycloalkyl; and

R^7 and R^8 are each, independently, selected from fluoro or CH_3, or R^7 and R^8 combine with the atoms to which they are attached to make a 3-membered cycloalkyl; wherein:

(i) the compound is not E10 to E52 in Table 2 and those set forth in Table 5; or

(ii) when A is thiazole-2,4-diyl and two R^{L1} substituents taken together form spiro cyclopropyl, then R^2 is not optionally substituted $C_{1\text{-}6}$ alkyl; or

(iii) when A is thiazole-2,4-diyl and two R^{L2} substituents taken together form spiro cyclopropyl, then R^2 is not optionally substituted $C_{1\text{-}6}$ alkyl; or

(iv) when A is thiazole-2,4-diyl and R^{L1} and R^{L2} taken together form optionally substituted fused cyclopropyl, then R^2 is not optionally substituted $C_{1\text{-}6}$ alkyl; or


(v) when A is thiazole-2,4-diyl and R^{L1} and R^{L2} taken together form a bond, then R^2 is not optionally substituted $C_{1\text{-}6}$ alkyl; or

(vi) when A is thiazole-2,4-diyl and R^{L1} and R^{L2} taken together form fused cyclobutyl, then R^2 is not optionally substituted $C_{1\text{-}6}$ alkyl; or

(vii) when A is thiazole-2,4-diyl and R^{L1} and R^{L3} together with the atoms to which they are attached form bridged cyclobutyl, then R^2 is not optionally substituted C_{1-6} alkyl; or

(viii) when A is thiazole-2,4-diyl and R^{L1} and R^{L3} together with the atoms to which they are attached form bridged cyclobutyl, then W is not optionally substituted cyclopropyl.

2. A compound, or pharmaceutically acceptable salt thereof, having the structure of Formula IV:




,

Formula IV

wherein A is optionally substituted 3- to 6-membered heterocycloalkylene, optionally substituted 3- to 6-membered cycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5- to 10-membered heteroarylene;


L^1 is a linker;

L has the structure of Formula VIIa or VIIb:



Formula VIIa

or









Formula VIIb












z is 0, 1, or 2;

X^9 is $-NR^{L6}-$, -C(O)-, or $-S(O)_2-$;

each of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} is, independently, hydrogen, halogen, hydroxyl, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, or optionally substituted C_1-C_6 heteroalkyl; or any two of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} together with the atoms to which they are attached and any intervening atoms to form an optionally substituted C_3-C_8 cycloalkyl or a 3- to 8-membered heterocyclyl;

wherein L does not have the structure of


,

,

,

,

, or

; or

optionally, wherein L is not

,

,

,

,

,

,

,

,

,

, or

;





W is a cross-linking group comprising a vinyl ketone, vinyl sulfone, ynone, or an alkynyl sulfone;





R^1 is hydrogen, optionally substituted 3- to 10-membered heterocycloalkyl, or optionally substituted C_1-C_6 heteroalkyl;

R^2 is optionally substituted C_1-C_6 alkyl; and

R^3 is optionally substituted C_1-C_6 alkyl or optionally substituted C_1-C_3 heteroalkyl;

(i) the compound is not:


,

,

,

,


,

,

, or

; or


(ii) when A is 1-hydroxy-benzene-3,5-diyl or optionally substituted phenylene, two R^{L1} substituents taken together form spiro cyclopropyl, and W is vinyl ketone, then R^2 is not ethyl; or

(iii) when A is 1-hydroxy-benzene-3,5-diyl or optionally substituted phenylene, R^{L1} and R^{L2} taken together form fused cyclopropyl, and W is vinyl ketone, then R^2 is not ethyl; or


(iv) when A is 1-hydroxy-benzene-3,5-diyl or optionally substituted phenylene and two R^{L1} substituents taken together form spiro cyclopropyl, then W is not vinyl ketone; or

(v) when A is 1-hydroxy-benzene-3,5-diyl or optionally substituted phenylene, R^{L1} and R^{L2} taken together form fused cyclopropyl, then W is not vinyl ketone; or


(vi) when A is 1-hydroxy-benzene-3,5-diyl or optionally substituted phenylene, W is vinyl ketone and two R^{L1} substituents taken together form spiro cyclopropyl or spiro cycloalkyl, then L^1 is other than


; or


(vii) when A is 1-hydroxy-benzene-3,5-diyl or optionally substituted phenylene, W is vinyl ketone and R^{L1} and R^{L2} taken together form fused cyclopropyl or fused cycloalkyl, then L^1 is not


; or


(viii) when A is 1-hydroxy-benzene-3,5-diyl or optionally substituted phenylene, W is vinyl ketone and two R^{L1} substituents taken together form spiro cyclopropyl or spiro cycloalkyl, then L^1 is not


optionally substituted with 1, 2 or 3 independently selected $C_{1\text{-}6}$ alkyl; or

(ix) when A is 1-hydroxy-benzene-3,5-diyl or optionally substituted phenylene, W is vinyl ketone and two R^{L1} and R^{L2} taken together form fused cyclopropyl or fused cycloalkyl, then L^1 is not


optionally substituted with 1, 2 or 3 independently selected $C_{1\text{-}6}$ alkyl.


3. A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula V:



Formula V


wherein A is optionally substituted 3- to 6-membered heterocycloalkylene, optionally substituted 3- to 6-membered cycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5- to 10-membered heteroarylene;

L has the structure of Formula VIIa or VIIb:



Formula VIIa

or




Formula VIIb

z is 0, 1, or 2;


X^9 is $-NR^{L6}-$, -C(O)-, or $-S(O)_2-$;

each of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} is, independently, hydrogen, halogen, hydroxyl, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, or optionally substituted C_1-C_6 heteroalkyl; or any two of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} together with the atoms to which they are attached and any intervening atoms to form an optionally substituted C_3-C_8 cycloalkyl or a 3- to 8-membered heterocyclyl;


wherein L does not have the structure of




,




,




,






,



, or



; or

optionally, wherein L is not , , or ;

W is a cross-linking group comprising an aziridine, an epoxide, a carbodiimide, an oxazoline, a thiazoline, a chloroethyl urea, a chloroethyl thiourea, a chloroethyl carbamate, a chloroethyl thiocarbamate, a trifluoromethyl ketone, a boronic acid, a boronic ester, an N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), an iso-EEDQ or other EEDQ derivative, an oxazolium, or a glycal;

X^6 is CH_2 or O;


m is 1 or 2;

n is 0 or 1;

R^1 is hydrogen or optionally substituted 3- to 10-membered heterocycloalkyl; and

R^2 is optionally substituted C_1-C_6 alkyl.


4. A compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula VI:




Formula VI

wherein A is optionally substituted 3- to 6-membered heterocycloalkylene, optionally substituted 3- to 6-membered cycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5- to 10-membered heteroarylene;




L has the structure of Formula VIIa or VIIb:



Formula VIIa

or 

Formula VIIb

optionally, wherein L is not , ; ;

z is 0, 1, or 2;

X^9 is $-NR^{L6}-$, -C(O)-, or $-S(O)_2-$;

each of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} is, independently, hydrogen, halogen, hydroxyl, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, or optionally substituted C_1-C_6 heteroalkyl; or any two of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} together with the atoms to which they are attached and any intervening atoms to form an optionally substituted C_3-C_8 cycloalkyl or a 3- to 8-membered heterocyclyl;

X^6, X^7, and X^8 are each independently selected from CH_2, CHF, CF_2, C=O, or O;

m is 1 or 2;

n is 0 or 1;


R^1 is hydrogen, optionally substituted C_1-C_6 heteroalkyl, or optionally substituted 3- to 10-membered heterocycloalkyl;

R^2 is optionally substituted C_1-C_6 alkyl; and

R^3 is optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted 3- to 6-membered cycloalkyl, or optionally substituted heterocycloalkyl,

and wherein each hydrogen is independently, optionally, isotopically enriched for deuterium.

5. A compound having Formula VIIIa:




Formula VIIIa


or a pharmaceutically acceptable salt thereof, wherein:

the dotted lines represent zero, one, two, three, or four non-adjacent double bonds;

L has the structure of Formula VIIa or VIIb:



or





Formula VIIa Formula VIIb


z is 0, 1, or 2;


X^9 is $-NR^{L6}-$, -C(O)-, or $-S(O)_2-$;


each of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} is, independently, hydrogen, halogen, hydroxyl, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted C_1-C_6 heteroalkyl, or optionally substituted C_3-C_8 cycloalkyl; or any two of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} together with the atoms to which they are attached and any intervening atoms to form an optionally substituted C_3-C_8 cycloalkyl or a 3- to 8-membered heterocyclyl;


wherein L does not have the structure of






,



,








,


,


, or

; or

optionally, wherein L is not

,

,

,


,


,

,

,

,

,

, or

;

A is optionally substituted C_2-C_4 alkylene, optionally substituted C_1-C_4 heteroalkylene, or optionally substituted C_2-C_4 alkenylene;

G is optionally substituted C_1-C_4 alkylene, optionally substituted C_1-C_4 alkenylene, optionally substituted C_1-C_4 heteroalkylene, -C(O)O-**C**H(R^6)- where **C** is bound to -C(R^7R^8)-, -C(O)NH-**C**H(R^6)- where **C** is bound to -C(R^7R^8)-, optionally substituted C_1-C_4 heteroalkylene, or 3 to 8-membered heteroarylene;

swIp (Switch I/P-loop) is an organic moiety that non-covalently binds to both the Switch I binding pocket and residues 12 or 13 of the P-loop of a Ras protein;

X^3 is N or CH;

Y^1 is C, CH, or N;

Y^2, Y^3, Y^4, and Y^7 are, independently, C or N;

Y^5 is CH, CH_2, or N;

Y^6 is C(O), CH, CH_2, or N;

R^1 is cyano, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted 3 to 6-membered cycloalkyl, optionally substituted 3 to 6-membered cycloalkenyl, optionally substituted 3 to 6-membered heterocycloalkyl, optionally substituted 6 to 10-membered aryl, or optionally substituted 5 to 10-membered heteroaryl, or

R^1 and R^2 combine with the atoms to which they are attached to form an optionally substituted 3 to 14-membered heterocycloalkyl;

R^2 is absent, hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted 3 to 6-membered cycloalkyl, optionally substituted 3 to 7-membered heterocycloalkyl, optionally substituted 6-membered aryl, optionally substituted 5 or 6-membered heteroaryl;

R^3 is absent, or

R^2 and R^3 combine with the atom to which they are attached to form an optionally substituted 3 to 8-membered cycloalkyl or optionally substituted 3 to 14-membered heterocycloalkyl;

R^4 is absent, hydrogen, halogen, cyano, or methyl optionally substituted with 1 to 3 halogens;

R^6 is hydrogen or methyl; R^7 is hydrogen, halogen, or optionally substituted C_1-C_3 alkyl, or

R^6 and R^7 combine with the carbon atoms to which they are attached to form an optionally substituted 3 to 6-membered cycloalkyl or optionally substituted 3 to 7-membered heterocycloalkyl;

R^8 is hydrogen, halogen, hydroxy, cyano, optionally substituted C_1-C_3 alkoxy, optionally substituted C_1-C_3 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted 3 to 8-membered cycloalkyl, optionally substituted 3 to 14-membered heterocycloalkyl, optionally substituted 5 to 10-membered heteroaryl, or optionally substituted 6 to 10-membered aryl, or

R^7 and R^8 combine with the carbon atom to which they are attached to form $C=CR^{7'}R^{8'}$; C=N(OH), C=N(O-C_1-C_3 alkyl), C=O, C=S, C=NH, optionally substituted 3 to 6-membered cycloalkyl, or optionally substituted 3 to 7-membered heterocycloalkyl;

R^{7a} and R^{8a} are, independently, hydrogen, halo, optionally substituted C_1-C_3 alkyl, or combine with the carbon to which they are attached to form a carbonyl;


$R^{7'}$ is hydrogen, halogen, or optionally substituted C_1-C_3 alkyl; $R^{8'}$ is hydrogen, halogen, hydroxy, cyano, optionally substituted C_1-C_3 alkoxy, optionally substituted C_1-C_3 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted 3 to 8-membered cycloalkyl, optionally substituted 3 to 14-membered heterocycloalkyl, optionally substituted 5 to 10-membered heteroaryl, or optionally substituted 6 to 10-membered aryl, or

$R^{7'}$ and $R^{8'}$ combine with the carbon atom to which they are attached to form optionally substituted 3 to 6-membered cycloalkyl or optionally substituted 3 to 7-membered heterocycloalkyl;


R^{10} is hydrogen, halo, hydroxy, C_1-C_3 alkoxy, or C_1-C_3 alkyl; and

R^{10a} is hydrogen or halo.


6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein the compound has formula VIIIb, VIIIc, VIIId, VIIIe, VIIIf or VIIIg:




Formula VIIIb ,




Formula VIIIc ,




Formula VIIId ,



,




, or



Formula VIIIe Formula VIIIf Formula VIIIg


wherein at each occurrence,

each L is independently having Formula VIIa or VIIb:



Formula VIIa

or




Formula VIIb

z is 0, 1, or 2;


X^9 is $-NR^{L6}-$, -C(O)-, or $-S(O)_2-$;

each of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} is, independently, hydrogen, halogen, hydroxyl, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted C_1-C_6 heteroalkyl, or optionally substituted C_3-C_8 cycloalkyl; or any two of R^{L1}, R^{L2}, R^{L3}, R^{L4}, R^{L4}, R^{L5}, and R^{L6} together with the atoms to which they are attached and any intervening atoms to form an optionally substituted C_3-C_8 cycloalkyl or a 3- to 8-membered heterocyclyl;


wherein L does not have the structure of




,




,




,



,



, or



;

G is optionally substituted C_1-C_4 alkylene, optionally substituted C_1-C_4 alkenylene, optionally substituted C_1-C_4 heteroalkylene, -C(O)O-**C**H(R^6)- where **C** is bound to -C(R^7R^8)-, -C(O)NH-**C**H(R^6)- where **C** is bound to -C(R^7R^8)-, optionally substituted C_1-C_4 heteroalkylene, or 3 to 8-membered heteroarylene;

Z is -C(O)- or $-S(O)_2-$;

each B is independently absent, -NH-, $-N(CH_3)-$, -O-, -CH(R^9)- or >C=C$R^9R^{9'}$ where the carbon is bound to the carbonyl carbon of -N(R^{11})C(O)-, optionally substituted 3 to 6-membered cycloalkylene, optionally substituted 3 to 6-membered heterocycloalkylene, optionally substituted 6-membered arylene, or 5 to 6-membered heteroarylene;

each L^1 is independently absent or a linker;

each W is independently hydrogen, cyano, optionally substituted amino, optionally substituted amido, optionally substituted C_1-C_4 alkoxy, optionally substituted C_1-C_4 hydroxyalkyl, optionally substituted C_1-C_4 aminoalkyl, optionally substituted C_1-C_4 haloalkyl, optionally substituted C_1-C_4 alkyl, optionally substituted C_1-C_4 guanidinoalkyl, C_0-C_4 alkyl optionally substituted 3 to 11-membered heterocycloalkyl, optionally substituted 3 to 10-membered cycloalkyl, optionally substituted 6 to 10-membered aryl, or optionally substituted 3 to 10-membered heteroaryl;

each X^3 is independently N or CH;

X^e is N, CH, or CR^{17};

X^f is N or CH;

R^{12} is optionally substituted C_1-C_6 alkyl or optionally substituted C_1-C_6 heteroalkyl;

R^{17} is optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted 3 to 6-membered cycloalkyl, optionally substituted 3 to 6-membered cycloalkenyl, optionally substituted 3 to 6-membered heterocycloalkyl, optionally substituted 6 to 10-membered aryl, or optionally substituted 5 to 10-membered heteroaryl.

each Y^1 is independently C, CH, or N;

Y^2, Y^3, Y^4, and Y^7 are, independently, C or N;

each Y^5 is independently CH, CH_2, or N;

each Y^6 is independently C(O), CH, CH_2, or N;

each R^1 is independently cyano, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted 3 to 6-membered cycloalkyl, optionally substituted 3 to 6-membered cycloalkenyl, optionally substituted 3 to 6-membered heterocycloalkyl, optionally substituted 6 to 10-membered aryl, or optionally substituted 5 to 10-membered heteroaryl, or

R^1 and R^2 combine with the atoms to which they are attached to form an optionally substituted 3 to 14-membered heterocycloalkyl;

each R^2 is independently absent, hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted 3 to 6-membered cycloalkyl, optionally substituted 3 to 7-membered heterocycloalkyl, optionally substituted 6-membered aryl, optionally substituted 5 or 6-membered heteroaryl;

each R^3 is independently absent, or

R^2 and R^3 combine with the atom to which they are attached to form an optionally substituted 3 to 8-membered cycloalkyl or optionally substituted 3 to 14-membered heterocycloalkyl;

each R^4 is independently absent, hydrogen, halogen, cyano, or methyl optionally substituted with 1 to 3 halogens;

each R^6 is independently hydrogen or methyl; each R^7 is independently hydrogen, halogen, or optionally substituted C_1-C_3 alkyl, or

R^6 and R^7 combine with the carbon atoms to which they are attached to form an optionally substituted 3 to 6-membered cycloalkyl or optionally substituted 3 to 7-membered heterocycloalkyl;

each R^8 is independently hydrogen, halogen, hydroxy, cyano, optionally substituted C_1-C_3 alkoxy, optionally substituted C_1-C_3 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted 3 to 8-membered cycloalkyl, optionally substituted 3 to 14-membered heterocycloalkyl, optionally substituted 5 to 10-membered heteroaryl, or optionally substituted 6 to 10-membered aryl, or

R^7 and R^8 combine with the carbon atom to which they are attached to form $C=CR^{7'}R^{8'}$; C=N(OH), C=N(O-C_1-C_3 alkyl), C=O, C=S, C=NH, optionally substituted 3 to 6-membered cycloalkyl, or optionally substituted 3 to 7-membered heterocycloalkyl;

R^{7a} and R^{8a} are, independently, hydrogen, halo, optionally substituted C_1-C_3 alkyl, or combine with the carbon to which they are attached to form a carbonyl;

$R^{7'}$ is hydrogen, halogen, or optionally substituted C_1-C_3 alkyl; $R^{8'}$ is hydrogen, halogen, hydroxy, cyano, optionally substituted C_1-C_3 alkoxy, optionally substituted C_1-C_3 alkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted 3 to 8-membered cycloalkyl, optionally substituted 3 to 14-membered heterocycloalkyl, optionally substituted 5 to 10-membered heteroaryl, or optionally substituted 6 to 10-membered aryl, or

$R^{7'}$ and $R^{8'}$ combine with the carbon atom to which they are attached to form optionally substituted 3 to 6-membered cycloalkyl or optionally substituted 3 to 7-membered heterocycloalkyl;

each R^9 is independently hydrogen, F, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted 3 to 6-membered cycloalkyl, or optionally substituted 3 to 7-membered heterocycloalkyl;


R^9 and L combine with the atoms to which they are attached to form an optionally substituted 3 to 14-membered heterocycloalkyl;


ach $R^{9'}$ is independently hydrogen or optionally substituted C_1-C_6 alkyl;


each R^{10} is independently hydrogen, halo, hydroxy, C_1-C_3 alkoxy, or C_1-C_3 alkyl;


R^{10a} is hydrogen or halo;


R^{11} is hydrogen or C_1-C_3 alkyl.


7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein L has the structure of Formula VIIa, Formula VIIa-1, Formula VIIa-2, Formula VIIa-3, Formula VIIa-4, Formula VIIa-5, Formula VIIa-6, Formula VIIb, Formula VIIb-1, Formula VIIb-2, or 
:



Formula VIIa



Formula VIIa-1



Formula VIIa-2



Formula VIIa-3



Formula VIIa-4


Formula VIIa-5


Formula VIIa-6


Formula VIIb


Formula VIIb-1


Formula VIIb-2

wherein X^9 is $-NR^{L6}-$; or X^9 is $-C(O)-$; or X^9 is $S(O)_2-$.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein z is 0; or z is 1; or z is 2.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R^{L1} is hydrogen; or R^{L1} is optionally substituted C_1-C_6 alkyl; or R^{L1} is methyl, ethyl, or trifluoromethyl; or R^{L1} is optionally substituted C_1-C_6 heteroalkyl; or R^{L1} is methoxy or ethoxy; R^{L1} is optionally substituted C_2-C_6 alkynyl; or R^{L1} is ethynyl.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^{L2} is hydrogen; or R^{L2} is halogen; or R^{L2} is fluoro.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R^{L3} is hydrogen; or R^{L3} is optionally substituted C_1-C_6 alkyl; or R^{L3} is methyl.

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein:

R^{L4} is hydrogen; or

R^{L1} and R^{L4} combine to form an optionally substituted C_4 cycloalkyl; or


R^{L1} and R^{L3} combine to form an optionally substituted C_4 cycloalkyl; or

R^{L1} and R^{L3} combine to form an optionally substituted C_5 cycloalkyl; or


two R^{L1} combine to form an optionally substituted C_3-C_6 cycloalkyl; or

R^{L1} and R^{L2} combine to form an optionally substituted C_3-C_6 cycloalkyl.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein L is:


, or ; or

L is:


, or .


14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein R^{L6} is optionally substituted C_1-C_6 alkyl; or R^{L6} is methyl.

15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^{L5} is hydrogen; or R^{L5} is optionally substituted C_1-C_6 alkyl; or R^{L5} is optionally substituted C_3-C_8 cycloalkyl; or two R^{L5} combine to form an optionally substituted C_3-C_8 cycloalkyl.



16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein:

A is optionally substituted 3- to 6-membered heterocycloalkylene, optionally substituted 6-membered arylene, or optionally substituted 5- to 10-membered heteroarylene; or


A is optionally substituted 6-membered arylene; or

A is  ; or

A is optionally substituted 3- to 6-membered heterocycloalkylene;

A is  or  ; or


A is optionally substituted 5- to 10-membered heteroarylene; or


A is  .




17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein R^2 is ethyl or haloethyl.




18. The compound of any one of claims 2 to 17, or a pharmaceutically acceptable salt thereof, wherein R^3 is optionally substituted C_1-C_6 alkyl.




19. A compound, or a pharmaceutically acceptable salt thereof, having the structure:




Ex#	Structure
A1	




Ex#	Structure
A2	




Ex#	Structure
A3	
A5	
A6	




Ex#	Structure
A7	
A8	
A9	




Ex#	Structure
A10	
A11	
A12	




Ex#	Structure
A13	
A14	
A15	




Ex#	Structure
A16	
A17	
A18	




Ex#	Structure
A19	
A20	
A21	




Ex#	Structure
A22	
A23	
A24	




Ex#	Structure
A25	
A26	
A27	




Ex#	Structure
A28	
A29	
A30	




Ex#	Structure
A31	
A32	
A33	




Ex#	Structure
A34	
A38	
A39	




Ex#	Structure
A40	
A42	
A43	



Ex#	Structure
A44	
A45	
A46	

Ex#	Structure
A47	
A48	
A49	

Ex#	Structure
A50	
A51	
A52	

Ex#	Structure
A53	
A54	
A55	

Ex#	Structure
A56	
A57	
A58	

Ex#	Structure
A59	
A60	

20. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of any one of claims 1 to 19 and a pharmaceutically acceptable excipient.

21. Use of a compound, or a pharmaceutically acceptable salt thereof, of any one of claims 1 to 19 or a pharmaceutical composition of claim 20, for the manufacture of a medicament for treating cancer;

optionally wherein the cancer is pancreatic cancer, colorectal cancer, non-small cell lung cancer, or endometrial cancer;

or optionally wherein the cancer comprises a Ras mutation; or

optionally wherein the method further comprises administering an additional anti-cancer therapy, optionally wherein the additional anti-cancer therapy is an EGFR inhibitor, a second Ras inhibitor, a SHP2 inhibitor, a SOS1 inhibitor, a Raf inhibitor, a MEK inhibitor, an ERK inhibitor, a PI3K inhibitor, a PTEN inhibitor, an AKT inhibitor, an mTORC1 inhibitor, a BRAF inhibitor, a PD-L1 inhibitor, a PD-1 inhibitor, a CDK4/6 inhibitor, a HER2 inhibitor, or a combination thereof.

22. Use of a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 20, for the manufacture of a medicament for treating a Ras protein-related disorder;

optionally wherein the Ras protein is K-Ras; or

optionally wherein the method further comprises administering an additional anti-cancer therapy, optionally wherein the additional anti-cancer therapy is an EGFR inhibitor, a second Ras inhibitor, a SHP2 inhibitor, a SOS1 inhibitor, a Raf inhibitor, a MEK inhibitor, an ERK inhibitor, a PI3K inhibitor, a PTEN inhibitor, an AKT inhibitor, an mTORC1 inhibitor, a BRAF inhibitor, a PD-L1 inhibitor, a PD-1 inhibitor, a CDK4/6 inhibitor, a HER2 inhibitor, or a combination thereof.

23. A method of inhibiting a Ras protein in a cell, the method comprising contacting the cell with an effective amount of a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 20,

optionally wherein the Ras protein is K-Ras;

or optionally wherein the cell is a cancer cell, optionally wherein the cancer cell is a pancreatic cancer cell, a colorectal cancer cell, a non-small cell lung cancer cell, or an endometrial cancer cell; or optionally wherein the method further comprises administering an additional anti-cancer therapy, optionally wherein the additional anti-cancer therapy is an EGFR inhibitor, a second Ras inhibitor, a SHP2 inhibitor, a SOS1 inhibitor, a Raf inhibitor, a MEK inhibitor, an ERK inhibitor, a PI3K inhibitor, a PTEN inhibitor, an AKT inhibitor, an mTORC1 inhibitor, a BRAF inhibitor, a PD-L1 inhibitor, a PD-1 inhibitor, a CDK4/6 inhibitor, a HER2 inhibitor, or a combination thereof.